Conformis (NASDAQ:CFMS) Coverage Initiated by Analysts at

Investment analysts at started coverage on shares of Conformis (NASDAQ:CFMSGet Rating) in a research report issued on Saturday. The brokerage set a “hold” rating on the medical instruments supplier’s stock.

Separately, Oppenheimer downgraded Conformis from an “outperform” rating to a “market perform” rating in a research note on Tuesday, May 9th.

Conformis Stock Performance

Shares of CFMS opened at $1.09 on Friday. Conformis has a 52-week low of $1.05 and a 52-week high of $11.25. The company has a quick ratio of 4.06, a current ratio of 5.71 and a debt-to-equity ratio of 0.46. The firm has a market cap of $8.18 million, a price-to-earnings ratio of -0.18 and a beta of 1.09. The business’s 50 day moving average is $1.42 and its two-hundred day moving average is $2.13.

Conformis (NASDAQ:CFMSGet Rating) last posted its quarterly earnings results on Wednesday, March 1st. The medical instruments supplier reported ($0.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.84) by $1.33. The firm had revenue of $17.42 million for the quarter, compared to analysts’ expectations of $13.84 million. Conformis had a negative net margin of 74.18% and a negative return on equity of 75.43%. Analysts forecast that Conformis will post -5.2 EPS for the current fiscal year.

Institutional Trading of Conformis

Institutional investors and hedge funds have recently modified their holdings of the business. Dimensional Fund Advisors LP bought a new position in Conformis in the fourth quarter worth about $91,000. Virtu Financial LLC bought a new position in Conformis during the 1st quarter worth $40,000. UBS Group AG increased its position in Conformis by 24.7% in the first quarter. UBS Group AG now owns 115,831 shares of the medical instruments supplier’s stock worth $186,000 after buying an additional 22,911 shares during the period. Jane Street Group LLC acquired a new stake in shares of Conformis in the 2nd quarter worth about $84,000. Finally, Bank of New York Mellon Corp raised its holdings in shares of Conformis by 2.3% during the third quarter. Bank of New York Mellon Corp now owns 368,020 shares of the medical instruments supplier’s stock valued at $71,000 after buying an additional 8,191 shares during the last quarter.

Conformis Company Profile

(Get Rating)

ConforMIS, Inc is a medical technology company, which engages in the development, manufacture, and sale of joint replacement implants. It operates through the following geographical segments: United States, Germany, and Rest of the World. The firm’s products include iUni, iDuo, iTotal CR, and iTotal.

Read More

Receive News & Ratings for Conformis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conformis and related companies with's FREE daily email newsletter.